Investment Rating - The report recommends an active participation in the company's IPO, indicating a favorable investment outlook with a PE (TTM) of 10.83, which is significantly lower than the industry average [24]. Core Insights - The company specializes in diabetes care and minimally invasive medical devices, with a strong market position in insulin pen needles and a successful expansion into high-growth minimally invasive intervention sectors [4][24]. - The company has shown steady revenue growth, with projected revenue of 318 million yuan in 2024, reflecting a CAGR of +14.74% over the past three years [10][24]. - The global demand for diabetes treatment is expected to continue growing, with the number of adult diabetes patients projected to reach 783 million by 2045 [16][17]. Summary by Sections 1. Company Overview - Established in 2013, the company focuses on the research, production, and sales of diabetes care and minimally invasive medical devices, with products sold in over 70 countries [4][9]. - The core product, insulin pen needles, has a notable market share, with projected sales of 1.175 billion units in 2024, increasing from 7.52% to 11.78% market share from 2022 to 2024 [4][9]. 2. Issuance Plan - The IPO will utilize a direct pricing method, with an issue price of 18.38 yuan per share and an initial issuance scale of 10.5828 million shares, representing 20% of the total post-issue share capital [14][15]. - The expected circulation ratio post-issue is 27.93%, with a moderate threshold for online subscription [14][15]. 3. Industry Situation - The demand for diabetes treatment is on the rise, with the prevalence of diabetes in China increasing from 8.8% in 2011 to 10.6% in 2021, and projected to reach 11.8% by 2030 [16][17]. - The industry is witnessing a trend towards high-end and intelligent product upgrades in minimally invasive medical devices [16][17]. 4. Competitive Advantages - The company has a strong R&D advantage, being one of the first domestic firms to introduce safety automatic self-destroying injection needles [18]. - It also boasts intelligent production capabilities, ensuring rapid industrialization of new products through advanced manufacturing technologies [18]. - The company has established a broad customer base across multiple continents, enhancing its market reputation and ability to respond to global demand [18]. 5. Comparable Companies - The company has a higher gross margin of 49.44% compared to its peers, indicating superior profitability [23].

Core Viewpoint - The article highlights the transformative impact of interventional therapy in cancer treatment, emphasizing the advantages of minimally invasive techniques over traditional methods like chemotherapy and surgery. Zhejiang Ganaiwei Medical Technology Co., Ltd. is positioned as a leader in this field, focusing on intelligent tumor intervention and treatment of common diseases [4][5]. Company Overview - Ganaiwei Medical specializes in intelligent tumor intervention and has developed a comprehensive treatment process that includes tumor biopsy, intelligent positioning, and energy ablation therapies. The company utilizes various energy ablation technologies such as radiofrequency ablation and pulsed electric field ablation [5][6]. - The company achieved a significant milestone in 2023 by obtaining FDA 510(K) certification for its composite pulsed electric field treatment system, making it the first Chinese and second global company to receive such certification for tumor treatment [6][7]. Technological Advancements - The composite pulsed electric field treatment system integrates low-frequency and high-frequency pulsed electric field ablation with radiofrequency thermal ablation, enhancing treatment efficacy and reducing the risk of cancer cell seeding and bleeding [6][7]. - Ganaiwei Medical has also developed a full range of biopsy products, including automatic and semi-automatic biopsy needles, which have received FDA and CE certifications and are exported to over 50 countries [7][8]. Research and Development - The company invests over 30% of its annual revenue into research and development, with a growing team of over 100 researchers. This commitment aims to create products that not only meet but exceed the standards of imported medical devices [8][9]. - Ganaiwei Medical has initiated the development of an intelligent puncture navigation robot named "Qianxing," designed to improve the success rate of puncture procedures and reduce complications [9]. Industry Context - The article discusses the role of private enterprises in driving technological innovation, highlighting their flexibility and efficiency in responding to market needs. Ganaiwei Medical aims to introduce innovative products that address current challenges in the healthcare sector [9].